Delaware – June 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of Oncology and Central Nervous system (CNS) compounds, announced today that Dr. Katrin Rupalla, PhD, MBA, is joining iQure’s Board of Directors.
Dr. Rupalla has vast experience in research and drug development with positions in various small, mid size and large Pharmaceutical Companies. She is currently Senior Vice President of Global Regulatory Affairs, Medical Documentation and R&D Quality at Lundbeck S/A in Copenhagen, Denmark.
About Dr. Rupalla:
Dr. Katrin Rupalla has more than 25 years experience in research & drug development, primarily in the areas of oncology, immunology and neurology. She is currently SVP, Global Head of Regulatory Affairs, Medical Documentation & R&D Quality at Lundbeck, Copenhagen, Denmark. Prior to joining Lundbeck, Dr. Rupalla worked in several leadership positions at Bristol-Myers Squibb, including as VP, Global Head of Regulatory Oncology based in Princeton, NJ, US and VP, Head of Development China based in Shanghai. Her Regulatory and Drug Development career includes several world-wide approvals of major products, such as REVLIMID®, OPDIVO® and YERVOY®, in the US, Europe and China as well as a multitude of new indication approvals. Dr. Rupalla is a certified pharmacist and obtained her PhD from Philipps University of Marburg, Germany in Pharmacology and Neurobiology and did postgraduate work in CNS Pharmacology at the University of Aachen/Novartis before starting her career in Drug Development at Roche.
Pawel Zolnierczyk, Chief Executive Officer:
We are delighted that Katrin has decided to join our Board and will help supervise our portfolio and development efforts. This is a great step forward for iQure, as Katrin’s expertise in regulatory affairs, oncology and neurology will be instrumental in iQure achieving critical project milestones that will enable us to continue to reach our key value inflection points.